RPPA-based protein profiling reveals eIF4G overexpression and 4E-BP1 serine 65 phosphorylation as molecular events that correspond with a pro-survival phenotype in chronic lymphocytic leukemia

Oncotarget

Volumn 6, Issue 16, 2015, Pages 14632-14645

  Shull, Austin Y ^a   Noonepalle, Satish K ^a   Awan, Farrukh T ^b   Liu, Jimei ^a   Pei, Lirong ^a   Bollag, Roni J ^a   Salman, Huda ^a   Ding, Zhiyong ^c   Shi, Huidong ^a  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

4E BP1; CLL; EIF4G; NVP BEZ235; RPPA

Indexed keywords

DACTOLISIB; IBRUTINIB; IDELALISIB; INITIATION FACTOR 4E BINDING PROTEIN 1; INITIATION FACTOR 4G; MESSENGER RNA; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; SERINE; EIF4EBP1 PROTEIN, HUMAN; NUCLEAR PROTEIN; PHOSPHOPROTEIN; SIGNAL TRANSDUCING ADAPTOR PROTEIN;

APOPTOSIS; ARTICLE; B LYMPHOCYTE; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; DRUG EFFICACY; DRUG POTENCY; EIF4G GENE; ENZYME PHOSPHORYLATION; GENE; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IC50; LEUKEMIA CELL LINE; PHENOTYPE; PROTEIN CLEAVAGE; PROTEIN DEPHOSPHORYLATION; PROTEIN MICROARRAY; PROTEIN PHOSPHORYLATION; REVERSE PHASE PROTEIN ARRAY ANALYSIS; SIGNAL TRANSDUCTION; SURVIVAL RATE; UPREGULATION; CELL PROLIFERATION; GENETICS; METABOLISM; MORTALITY; PHOSPHORYLATION; PROCEDURES; TUMOR CELL LINE;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; CELL LINE, TUMOR; CELL PROLIFERATION; EUKARYOTIC INITIATION FACTOR-4G; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; NUCLEAR PROTEINS; PHENOTYPE; PHOSPHOPROTEINS; PHOSPHORYLATION; PROTEIN ARRAY ANALYSIS; SERINE; SIGNAL TRANSDUCTION;

EID: 84931037273     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.4104     Document Type: Article

References (83)

1. Furman RR. Prognostic markers and stratification of chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program. 2010; 2010:77-81.
2. Landau DA, Carter SL, Stojanov P, McKenna A, Stevenson K, Lawrence MS, Sougnez C, Stewart C, Sivachenko A, Wang L, Wan Y, Zhang W, Shukla SA, Vartanov A, Fernandes SM, Saksena G, et al. Evolution and impact of subclonal mutations in chronic lymphocytic leukemia. Cell. 2013; 152:714-726.
3. Landau DA, Clement K, Ziller MJ, Boyle P, Fan J, Gu H, Stevenson K, Sougnez C, Wang L, Li S, Kotliar D, Zhang W, Ghandi M, Garraway L, Fernandes SM, Livak KJ, et al. Locally disordered methylation forms the basis of intratumor methylome variation in chronic lymphocytic leukemia. Cancer Cell. 2014; 26:813-825.
4. Quesada V, Conde L, Villamor N, Ordonez GR, Jares P, Bassaganyas L, Ramsay AJ, Bea S, Pinyol M, Martinez- Trillos A, Lopez-Guerra M, Colomer D, Navarro A, Baumann T, Aymerich M, Rozman M, et al. Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia. Nat Genet. 2012; 44:47-52.
5. Cortese D, Sutton LA, Cahill N, Smedby KE, Geisler C, Gunnarsson R, Juliusson G, Mansouri L and Rosenquist R. On the way towards a 'CLL prognostic index': focus on TP53, BIRC3, SF3B1, NOTCH1 and MYD88 in a population-based cohort. Leukemia. 2014; 28:710-713.
6. Puente XS, Pinyol M, Quesada V, Conde L, Ordonez GR, Villamor N, Escaramis G, Jares P, Bea S, Gonzalez-Diaz M, Bassaganyas L, Baumann T, Juan M, Lopez-Guerra M, Colomer D, Tubio JM, et al. Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature. 2011; 475:101-105.
7. Duzkale H, Schweighofer CD, Coombes KR, Barron LL, Ferrajoli A, O'Brien S, Wierda WG, Pfeifer J, Majewski T, Czerniak BA, Jorgensen JL, Medeiros LJ, Freireich EJ, Keating MJ and Abruzzo LV. LDOC1 mRNA is differentially expressed in chronic lymphocytic leukemia and predicts overall survival in untreated patients. Blood. 2011; 117:4076-4084.
8. Jantus Lewintre E, Reinoso Martin C, Montaner D, Marin M, Jose Terol M, Farras R, Benet I, Calvete JJ, Dopazo J and Garcia-Conde J. Analysis of chronic lymphotic leukemia transcriptomic profile: differences between molecular subgroups. Leuk Lymphoma. 2009; 50:68-79.
9. Eisele L, Prinz R, Klein-Hitpass L, Nuckel H, Lowinski K, Thomale J, Moeller LC, Duhrsen U and Durig J. Combined PER2 and CRY1 expression predicts outcome in chronic lymphocytic leukemia. Eur J Haematol. 2009; 83:320-327.
10. Hanoun M, Eisele L, Suzuki M, Greally JM, Huttmann A, Aydin S, Scholtysik R, Klein-Hitpass L, Duhrsen U and Durig J. Epigenetic silencing of the circadian clock gene CRY1 is associated with an indolent clinical course in chronic lymphocytic leukemia. PLoS One. 2012; 7:e34347.
11. Cahill N, Bergh AC, Kanduri M, Goransson-Kultima H, Mansouri L, Isaksson A, Ryan F, Smedby KE, Juliusson G, Sundstrom C, Rosen A and Rosenquist R. 450K-array analysis of chronic lymphocytic leukemia cells reveals global DNA methylation to be relatively stable over time and similar in resting and proliferative compartments. Leukemia. 2013; 27:150-158.
12. Mansouri L, Gunnarsson R, Sutton LA, Ameur A, Hooper SD, Mayrhofer M, Juliusson G, Isaksson A, Gyllensten U and Rosenquist R. Next generation RNA-sequencing in prognostic subsets of chronic lymphocytic leukemia. Am J Hematol. 2012; 87:737-740.
13. Mansouri M, Sevov M, Fahlgren E, Tobin G, Jondal M, Osorio L, Roos G, Olivecrona G and Rosenquist R. Lipoprotein lipase is differentially expressed in prognostic subsets of chronic lymphocytic leukemia but displays invariably low catalytical activity. Leuk Res. 2010; 34:301-306.
14. Maloum K, Settegrana C, Chapiro E, Cazin B, Lepretre S, Delmer A, Leporrier M, Dreyfus B, Tournilhac O, Mahe B, Nguyen-Khac F, Lesty C, Davi F and Merle-Beral H. IGHV gene mutational status and LPL/ADAM29 gene expression as clinical outcome predictors in CLL patients in remission following treatment with oral fludarabine plus cyclophosphamide. Ann Hematol. 2009; 88:1215-1221.
15. Pei L, Choi JH, Liu J, Lee EJ, McCarthy B, Wilson JM, Speir E, Awan F, Tae H, Arthur G, Schnabel JL, Taylor KH, Wang X, Xu D, Ding HF, Munn DH, et al. Genomewide DNA methylation analysis reveals novel epigenetic changes in chronic lymphocytic leukemia. Epigenetics. 2012; 7:567-578.
16. Kulis M, Heath S, Bibikova M, Queiros AC, Navarro A, Clot G, Martinez-Trillos A, Castellano G, Brun-Heath I, Pinyol M, Barberan-Soler S, Papasaikas P, Jares P, Bea S, Rico D, Ecker S, et al. Epigenomic analysis detects widespread gene-body DNA hypomethylation in chronic lymphocytic leukemia. Nat Genet. 2012; 44:1236-1242.
17. Kanduri M, Cahill N, Goransson H, Enstrom C, Ryan F, Isaksson A and Rosenquist R. Differential genome-wide array-based methylation profiles in prognostic subsets of chronic lymphocytic leukemia. Blood. 2010; 115:296-305.
18. Agathangelidis A, Ntoufa S and Stamatopoulos K. B cell receptor and antigens in CLL. Adv Exp Med Biol. 2013; 792:1-24.
19. Stevenson FK, Krysov S, Davies AJ, Steele AJ and Packham G. B-cell receptor signaling in chronic lymphocytic leukemia. Blood. 2011; 118:4313-4320.
20. Robak T and Robak P. BCR signaling in chronic lymphocytic leukemia and related inhibitors currently in clinical studies. Int Rev Immunol. 2013; 32:358-376.
21. Burger JA. Inhibiting B-cell receptor signaling pathways in chronic lymphocytic leukemia. Curr Hematol Malig Rep. 2012; 7:26-33.
22. Herishanu Y, Perez-Galan P, Liu D, Biancotto A, Pittaluga S, Vire B, Gibellini F, Njuguna N, Lee E, Stennett L, Raghavachari N, Liu P, McCoy JP, Raffeld M, Stetler-Stevenson M, Yuan C, et al. The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia. Blood. 2011; 117:563-574.
23. Herman SE, Gordon AL, Hertlein E, Ramanunni A, Zhang X, Jaglowski S, Flynn J, Jones J, Blum KA, Buggy JJ, Hamdy A, Johnson AJ and Byrd JC. Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. Blood. 2011; 117:6287-6296.
24. Byrd JC, Furman RR, Coutre SE, Flinn IW, Burger JA, Blum KA, Grant B, Sharman JP, Coleman M, Wierda WG, Jones JA, Zhao W, Heerema NA, Johnson AJ, Sukbuntherng J, Chang BY, et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med. 2013; 369:32-42.
25. Furman RR, Sharman JP, Coutre SE, Cheson BD, Pagel JM, Hillmen P, Barrientos JC, Zelenetz AD, Kipps TJ, Flinn I, Ghia P, Eradat H, Ervin T, Lamanna N, Coiffier B, Pettitt AR, et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med. 2014; 370:997-1007.
26. Brown JR, Byrd JC, Coutre SE, Benson DM, Flinn IW, Wagner-Johnston ND, Spurgeon SE, Kahl BS, Bello C, Webb HK, Johnson DM, Peterman S, Li D, Jahn TM, Lannutti BJ, Ulrich RG, et al. Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110delta, for relapsed/refractory chronic lymphocytic leukemia. Blood. 2014; 123:3390-3397.
27. Fiorcari S, Brown WS, McIntyre BW, Estrov Z, Maffei R, O'Brien S, Sivina M, Hoellenriegel J, Wierda WG, Keating MJ, Ding W, Kay NE, Lannutti BJ, Marasca R and Burger JA. The PI3-kinase delta inhibitor idelalisib (GS-1101) targets integrin-mediated adhesion of chronic lymphocytic leukemia (CLL) cell to endothelial and marrow stromal cells. PLoS One. 2013; 8:e83830.
28. Fukuchi-Shimogori T, Ishii I, Kashiwagi K, Mashiba H, Ekimoto H and Igarashi K. Malignant transformation by overproduction of translation initiation factor eIF4G. Cancer Res. 1997; 57:5041-5044.
29. Li G, He S, Chang L, Lu H, Zhang H and Chiu J. GADD45alpha and annexin A1 are involved in the apoptosis of HL-60 induced by resveratrol. Phytomedicine. 2011; 18:704-709.
30. Zhu F, Wang Y, Zeng S, Fu X, Wang L and Cao J. Involvement of annexin A1 in multidrug resistance of K562/ADR cells identified by the proteomic study. Omics. 2009; 13:467-476.
31. King D, Pringle JH, Hutchinson M and Cohen GM. Processing/activation of caspases, -3 and -7 and -8 but not caspase-2, in the induction of apoptosis in B-chronic lymphocytic leukemia cells. Leukemia. 1998; 12:1553-1560.
32. Talab F, Allen JC, Thompson V, Lin K and Slupsky JR. LCK is an important mediator of B-cell receptor signaling in chronic lymphocytic leukemia cells. Mol Cancer Res. 2013; 11:541-554.
33. Spurgeon SE, Coffey G, Fletcher LB, Burke R, Tyner JW, Druker BJ, Betz A, DeGuzman F, Pak Y, Baker D, Pandey A, Hollenbach SJ, Sinha U and Loriaux MM. The selective SYK inhibitor P505-15 (PRT062607) inhibits B cell signaling and function in vitro and in vivo and augments the activity of fludarabine in chronic lymphocytic leukemia. J Pharmacol Exp Ther. 2013; 344:378-387.
34. Hoellenriegel J, Coffey GP, Sinha U, Pandey A, Sivina M, Ferrajoli A, Ravandi F, Wierda WG, O'Brien S, Keating MJ and Burger JA. Selective, novel spleen tyrosine kinase (Syk) inhibitors suppress chronic lymphocytic leukemia B-cell activation and migration. Leukemia. 2012; 26:1576-1583.
35. Buchner M, Fuchs S, Prinz G, Pfeifer D, Bartholome K, Burger M, Chevalier N, Vallat L, Timmer J, Gribben JG, Jumaa H, Veelken H, Dierks C and Zirlik K. Spleen tyrosine kinase is overexpressed and represents a potential therapeutic target in chronic lymphocytic leukemia. Cancer Res. 2009; 69:5424-5432.
36. Del Gaizo Moore V, Brown JR, Certo M, Love TM, Novina CD and Letai A. Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737. J Clin Invest. 2007; 117:112-121.
37. Masood A, Chitta K, Paulus A, Khan AN, Sher T, Ersing N, Miller KC, Manfredi D, Ailawadhi S, Borrelo I, Lee KP and Chanan-Khan A. Downregulation of BCL2 by AT-101 enhances the antileukaemic effect of lenalidomide both by an immune dependant and independent manner. Br J Haematol. 2012; 157:59-66.
38. Paterson A, Mockridge CI, Adams JE, Krysov S, Potter KN, Duncombe AS, Cook SJ, Stevenson FK and Packham G. Mechanisms and clinical significance of BIM phosphorylation in chronic lymphocytic leukemia. Blood. 2012; 119:1726-1736.
39. Scarfo L and Ghia P. Reprogramming cell death: BCL2 family inhibition in hematological malignancies. Immunol Lett. 2013; 155:36-39.
40. Rosati E, Sabatini R, Rampino G, Tabilio A, Di Ianni M, Fettucciari K, Bartoli A, Coaccioli S, Screpanti I and Marconi P. Constitutively activated Notch signaling is involved in survival and apoptosis resistance of B-CLL cells. Blood. 2009; 113:856-865.
41. Baldoni S, Sportoletti P, Del Papa B, Aureli P, Dorillo E, Rosati E, Ciurnelli R, Marconi P, Falzetti F and Di Ianni M. NOTCH and NF-kappaB interplay in chronic lymphocytic leukemia is independent of genetic lesion. Int J Hematol. 2013; 98:153-157.
42. Ren D, Tu HC, Kim H, Wang GX, Bean GR, Takeuchi O, Jeffers JR, Zambetti GP, Hsieh JJ and Cheng EH. BID, BIM, and PUMA are essential for activation of the BAXand BAK-dependent cell death program. Science. 2010; 330:1390-1393.
43. Jiang M, Pabla N, Murphy RF, Yang T, Yin XM, Degenhardt K, White E and Dong Z. Nutlin-3 protects kidney cells during cisplatin therapy by suppressing Bax/Bak activation. J Biol Chem. 2007; 282:2636-2645.
44. Pohland T, Wagner S, Mahyar-Roemer M and Roemer K. Bax and Bak are the critical complementary effectors of colorectal cancer cell apoptosis by chemopreventive resveratrol. Anticancer Drugs. 2006; 17:471-478.
45. Kafka A, Tomas D, Beros V, Pecina HI, Zeljko M and Pecina-Slaus N. Brain metastases from lung cancer show increased expression of DVL1, DVL3 and beta-catenin and down-regulation of E-cadherin. Int J Mol Sci. 2014; 15:10635-10651.
46. Haddad BR, Gu L, Mirtti T, Dagvadorj A, Vogiatzi P, Hoang DT, Bajaj R, Leiby B, Ellsworth E, Blackmon S, Ruiz C, Curtis M, Fortina P, Ertel A, Liu C, Rui H, et al. STAT5A/B gene locus undergoes amplification during human prostate cancer progression. Am J Pathol. 2013; 182:2264-2275.
47. Boussemart L, Malka-Mahieu H, Girault I, Allard D, Hemmingsson O, Tomasic G, Thomas M, Basmadjian C, Ribeiro N, Thuaud F, Mateus C, Routier E, Kamsu-Kom N, Agoussi S, Eggermont AM, Desaubry L, et al. eIF4F is a nexus of resistance to anti-BRAF and anti-MEK cancer therapies. Nature. 2014; 513:105-109.
48. Cagnol S and Rivard N. Oncogenic KRAS and BRAF activation of the MEK/ERK signaling pathway promotes expression of dual-specificity phosphatase 4 (DUSP4/MKP2) resulting in nuclear ERK1/2 inhibition. Oncogene. 2013; 32:564-576.
49. Lu Y, Muller M, Smith D, Dutta B, Komurov K, Iadevaia S, Ruths D, Tseng JT, Yu S, Yu Q, Nakhleh L, Balazsi G, Donnelly J, Schurdak M, Morgan-Lappe S, Fesik S, et al. Kinome siRNA-phosphoproteomic screen identifies networks regulating AKT signaling. Oncogene. 2011; 30:4567-4577.
50. Ringshausen I, Peschel C and Decker T. Mammalian target of rapamycin (mTOR) inhibition in chronic lymphocytic B-cell leukemia: a new therapeutic option. Leuk Lymphoma. 2005; 46:11-19.
51. Jung CH, Ro SH, Cao J, Otto NM and Kim DH. mTOR regulation of autophagy. FEBS Lett. 2010; 584:1287-1295.
52. Annovazzi L, Mellai M, Caldera V, Valente G, Tessitore L and Schiffer D. mTOR, S6 and AKT expression in relation to proliferation and apoptosis/autophagy in glioma. Anticancer Res. 2009; 29:3087-3094.
53. Zeng H and Chi H. mTOR and lymphocyte metabolism. Curr Opin Immunol. 2013; 25:347-355.
54. Cornu M, Albert V and Hall MN. mTOR in aging, metabolism, and cancer. Curr Opin Genet Dev. 2013; 23:53-62.
55. Cuconati A, Mills C, Goddard C, Zhang X, Yu W, Guo H, Xu X and Block TM. Suppression of AKT anti-apoptotic signaling by a novel drug candidate results in growth arrest and apoptosis of hepatocellular carcinoma cells. PLoS One. 2013; 8:e54595.
56. Rassidakis GZ, Feretzaki M, Atwell C, Grammatikakis I, Lin Q, Lai R, Claret FX, Medeiros LJ and Amin HM. Inhibition of Akt increases p27Kip1 levels and induces cell cycle arrest in anaplastic large cell lymphoma. Blood. 2005; 105:827-829.
57. Rathmell JC, Fox CJ, Plas DR, Hammerman PS, Cinalli RM and Thompson CB. Akt-directed glucose metabolism can prevent Bax conformation change and promote growth factor-independent survival. Mol Cell Biol. 2003; 23:7315-7328.
58. Whiteman EL, Cho H and Birnbaum MJ. Role of Akt/protein kinase B in metabolism. Trends Endocrinol Metab. 2002; 13:444-451.
59. Dunn GP, Cheung HW, Agarwalla PK, Thomas S, Zektser Y, Karst AM, Boehm JS, Weir BA, Berlin AM, Zou L, Getz G, Liu JF, Hirsch M, Vazquez F, Root DE, Beroukhim R, et al. In vivo multiplexed interrogation of amplified genes identifies GAB2 as an ovarian cancer oncogene. Proc Natl Acad Sci U S A. 2014; 111:1102-1107.
60. Bocanegra M, Bergamaschi A, Kim YH, Miller MA, Rajput AB, Kao J, Langerod A, Han W, Noh DY, Jeffrey SS, Huntsman DG, Borresen-Dale AL and Pollack JR. Focal amplification and oncogene dependency of GAB2 in breast cancer. Oncogene. 2010; 29:774-779.
61. Daly RJ, Gu H, Parmar J, Malaney S, Lyons RJ, Kairouz R, Head DR, Henshall SM, Neel BG and Sutherland RL. The docking protein Gab2 is overexpressed and estrogen regulated in human breast cancer. Oncogene. 2002; 21:5175-5181.
62. Hao Y, Zhao S and Wang Z. Targeting the protein-protein interaction between IRS1 and mutant p110alpha for cancer therapy. Toxicol Pathol. 2014; 42:140-147.
63. Porter HA, Perry A, Kingsley C, Tran NL and Keegan AD. IRS1 is highly expressed in localized breast tumors and regulates the sensitivity of breast cancer cells to chemotherapy, while IRS2 is highly expressed in invasive breast tumors. Cancer Lett. 2013; 338:239-248.
64. Im-aram A, Farrand L, Bae SM, Song G, Song YS, Han JY and Tsang BK. The mTORC2 component rictor contributes to cisplatin resistance in human ovarian cancer cells. PLoS One. 2013; 8:e75455.
65. McDonald PC, Oloumi A, Mills J, Dobreva I, Maidan M, Gray V, Wederell ED, Bally MB, Foster LJ and Dedhar S. Rictor and integrin-linked kinase interact and regulate Akt phosphorylation and cancer cell survival. Cancer Res. 2008; 68:1618-1624.
66. Karni R, Hippo Y, Lowe SW and Krainer AR. The splicingfactor oncoprotein SF2/ASF activates mTORC1. Proc Natl Acad Sci U S A. 2008; 105:15323-15327.
67. Michlewski G, Sanford JR and Caceres JF. The splicing factor SF2/ASF regulates translation initiation by enhancing phosphorylation of 4E-BP1. Mol Cell. 2008; 30:179-189.
68. Gingras AC, Kennedy SG, O'Leary MA, Sonenberg N and Hay N. 4E-BP1, a repressor of mRNA translation, is phosphorylated and inactivated by the Akt(PKB) signaling pathway. Genes Dev. 1998; 12:502-513.
69. Chapuis N, Tamburini J, Green AS, Vignon C, Bardet V, Neyret A, Pannetier M, Willems L, Park S, Macone A, Maira SM, Ifrah N, Dreyfus F, Herault O, Lacombe C, Mayeux P, et al. Dual inhibition of PI3K and mTORC1/2 signaling by NVP-BEZ235 as a new therapeutic strategy for acute myeloid leukemia. Clin Cancer Res. 2010; 16:5424-5435.
70. Herman SE, Gordon AL, Wagner AJ, Heerema NA, Zhao W, Flynn JM, Jones J, Andritsos L, Puri KD, Lannutti BJ, Giese NA, Zhang X, Wei L, Byrd JC and Johnson AJ. Phosphatidylinositol 3-kinase-delta inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals. Blood. 2010; 116:2078-2088.
71. Shehata M, Schnabl S, Demirtas D, Tauber S, Hilgarth M, Bilban M, Vanura K, Porpaczy E, Fonatsch C, Stilgenbauer S, Schwarzmeier JD, Hubmann R, Gaiger A, Zielinski C, Maira S-M, Garcia-Echeverria C, et al. Effective Targeting of the PI3-K Pathway in CLL with NVP-BEZ235, a Novel Orally Available Dual PI3K/mTOR Inhibitor. ASH Annual Meeting Abstracts. 2008; 112:3166.
72. Titanji K, Velu V, Chennareddi L, Vijay-Kumar M, Gewirtz AT, Freeman GJ and Amara RR. Acute depletion of activated memory B cells involves the PD-1 pathway in rapidly progressing SIV-infected macaques. J Clin Invest. 2010; 120:3878-3890.
73. Bushell M, Poncet D, Marissen WE, Flotow H, Lloyd RE, Clemens MJ and Morley SJ. Cleavage of polypeptide chain initiation factor eIF4GI during apoptosis in lymphoma cells: characterisation of an internal fragment generated by caspase-3-mediated cleavage. Cell Death Differ. 2000; 7:628-636.
74. Badura M, Braunstein S, Zavadil J and Schneider RJ. DNA damage and eIF4G1 in breast cancer cells reprogram translation for survival and DNA repair mRNAs. Proc Natl Acad Sci U S A. 2012; 109:18767-18772.
75. Vikhreva PN, Shepelev MV and Korobko IV. mTORdependent transcriptional repression of Pdcd4 tumor suppressor in lung cancer cells. Biochim Biophys Acta. 2014; 1839:43-49.
76. Garami A, Zwartkruis FJ, Nobukuni T, Joaquin M, Roccio M, Stocker H, Kozma SC, Hafen E, Bos JL and Thomas G. Insulin activation of Rheb, a mediator of mTOR/S6K/4EBP signaling, is inhibited by TSC1 and 2. Mol Cell. 2003; 11:1457-1466.
77. Liu J, Stevens PD, Eshleman NE and Gao T. Protein phosphatase PPM1G regulates protein translation and cell growth by dephosphorylating 4E binding protein 1 (4EBP1). J Biol Chem. 2013; 288:23225-23233.
78. Ferreira PG, Jares P, Rico D, Gomez-Lopez G, Martinez- Trillos A, Villamor N, Ecker S, Gonzalez-Perez A, Knowles DG, Monlong J, Johnson R, Quesada V, Djebali S, Papasaikas P, Lopez-Guerra M, Colomer D, et al. Transcriptome characterization by RNA sequencing identifies a major molecular and clinical subdivision in chronic lymphocytic leukemia. Genome Res. 2014; 24:212-226.
79. Karni R, de Stanchina E, Lowe SW, Sinha R, Mu D and Krainer AR. The gene encoding the splicing factor SF2/ASF is a proto-oncogene. Nat Struct Mol Biol. 2007; 14:185-193.
80. Anczukow O, Rosenberg AZ, Akerman M, Das S, Zhan L, Karni R, Muthuswamy SK and Krainer AR. The splicing factor SRSF1 regulates apoptosis and proliferation to promote mammary epithelial cell transformation. Nat Struct Mol Biol. 2012; 19:220-228.
81. Wan X, Harkavy B, Shen N, Grohar P and Helman LJ. Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism. Oncogene. 2007; 26:1932-1940.
82. Decker T, Sandherr M, Goetze K, Oelsner M, Ringshausen I and Peschel C. A pilot trial of the mTOR (mammalian target of rapamycin) inhibitor RAD001 in patients with advanced B-CLL. Ann Hematol. 2009; 88:221-227.
83. Willimott S, Beck D, Ahearne MJ, Adams VC and Wagner SD. Cap-translation inhibitor, 4EGI-1, restores sensitivity to ABT-737 apoptosis through cap-dependent and -independent mechanisms in chronic lymphocytic leukemia. Clin Cancer Res. 2013; 19:3212-3223.